Northern Trust Corp raised its holdings in shares of Syndax Pharmaceuticals Inc (NASDAQ:SNDX) by 94.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 130,196 shares of the company’s stock after acquiring an additional 63,336 shares during the quarter. Northern Trust Corp owned about 0.71% of Syndax Pharmaceuticals worth $1,819,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also recently added to or reduced their stakes in SNDX. New York State Common Retirement Fund boosted its holdings in shares of Syndax Pharmaceuticals by 421.9% during the second quarter. New York State Common Retirement Fund now owns 9,400 shares of the company’s stock worth $131,000 after purchasing an additional 7,599 shares during the period. Airain ltd bought a new position in Syndax Pharmaceuticals in the second quarter worth about $150,000. Bank of Montreal Can bought a new position in Syndax Pharmaceuticals in the second quarter worth about $158,000. Teachers Advisors LLC raised its stake in Syndax Pharmaceuticals by 109.9% in the second quarter. Teachers Advisors LLC now owns 15,451 shares of the company’s stock worth $216,000 after buying an additional 8,091 shares in the last quarter. Finally, Alps Advisors Inc. bought a new position in Syndax Pharmaceuticals in the second quarter worth about $277,000. 61.69% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Syndax Pharmaceuticals Inc (NASDAQ SNDX) opened at $8.40 on Monday. Syndax Pharmaceuticals Inc has a fifty-two week low of $6.31 and a fifty-two week high of $15.70.
Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings results on Tuesday, November 7th. The company reported ($0.68) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.80) by $0.12. The business had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $0.30 million. Syndax Pharmaceuticals had a negative net margin of 4,304.34% and a negative return on equity of 57.90%. The company’s revenue was up .0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.84) EPS. sell-side analysts predict that Syndax Pharmaceuticals Inc will post -3.03 earnings per share for the current fiscal year.
A number of equities analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 17th. Instinet reaffirmed a “buy” rating and set a $22.00 target price (down previously from $27.00) on shares of Syndax Pharmaceuticals in a research note on Monday, August 14th. Two investment analysts have rated the stock with a sell rating and eight have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $23.13.
ILLEGAL ACTIVITY WARNING: “Northern Trust Corp Boosts Stake in Syndax Pharmaceuticals Inc (SNDX)” was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://ledgergazette.com/2017/12/11/northern-trust-corp-has-1-82-million-position-in-syndax-pharmaceuticals-inc-sndx.html.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.
Receive News & Ratings for Syndax Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.